Solara Active Pharma Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Solara Active Pharma Sciences has a total shareholder equity of ₹10.9B and total debt of ₹8.2B, which brings its debt-to-equity ratio to 75.3%. Its total assets and total liabilities are ₹22.9B and ₹12.0B respectively.
Key information
75.3%
Debt to equity ratio
₹8.20b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹60.70m |
| Equity | ₹10.89b |
| Total liabilities | ₹12.01b |
| Total assets | ₹22.90b |
Recent financial health updates
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Recent updates
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More
Sep 13Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce
Jul 20Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
May 11Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump
Apr 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21Financial Position Analysis
Short Term Liabilities: SOLARA's short term assets (₹7.6B) do not cover its short term liabilities (₹10.5B).
Long Term Liabilities: SOLARA's short term assets (₹7.6B) exceed its long term liabilities (₹1.5B).
Debt to Equity History and Analysis
Debt Level: SOLARA's net debt to equity ratio (74.7%) is considered high.
Reducing Debt: SOLARA's debt to equity ratio has increased from 58.2% to 75.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SOLARA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SOLARA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.7% per year.